Matches in Nanopublications for { ?s ?p "[Recently, recombinant factor VIIa concentrate has become available to treat hemophilia patients with inhibitor and factor VII deficiency patients in Europe and also recombinant factor IX for the treatment of hemophilia B has been licensed in the United States and Europe.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP308867.RAd8ookVKkZ6ryCNFBUcAIsphbo_cHNIOhWxATIf7J3sY130_assertion description "[Recently, recombinant factor VIIa concentrate has become available to treat hemophilia patients with inhibitor and factor VII deficiency patients in Europe and also recombinant factor IX for the treatment of hemophilia B has been licensed in the United States and Europe.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308867.RAd8ookVKkZ6ryCNFBUcAIsphbo_cHNIOhWxATIf7J3sY130_provenance.
- assertion description "[Recently, recombinant factor VIIa concentrate has become available to treat hemophilia patients with inhibitor and factor VII deficiency patients in Europe and also recombinant factor IX for the treatment of hemophilia B has been licensed in the United States and Europe.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Recently, recombinant factor VIIa concentrate has become available to treat hemophilia patients with inhibitor and factor VII deficiency patients in Europe and also recombinant factor IX for the treatment of hemophilia B has been licensed in the United States and Europe.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP392471.RA9aCXkkN0TAAx5UPB68C-I4aLzdS_t3P3RNbS_c8AqiM130_assertion description "[Recently, recombinant factor VIIa concentrate has become available to treat hemophilia patients with inhibitor and factor VII deficiency patients in Europe and also recombinant factor IX for the treatment of hemophilia B has been licensed in the United States and Europe.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP392471.RA9aCXkkN0TAAx5UPB68C-I4aLzdS_t3P3RNbS_c8AqiM130_provenance.
- NP283434.RAMh4EOHKJ5lAuYp_sSYZx9UK7NB18Lh8iutBVqCb0YA4130_assertion description "[Recently, recombinant factor VIIa concentrate has become available to treat hemophilia patients with inhibitor and factor VII deficiency patients in Europe and also recombinant factor IX for the treatment of hemophilia B has been licensed in the United States and Europe.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP283434.RAMh4EOHKJ5lAuYp_sSYZx9UK7NB18Lh8iutBVqCb0YA4130_provenance.
- NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_assertion description "[Recently, recombinant factor VIIa concentrate has become available to treat hemophilia patients with inhibitor and factor VII deficiency patients in Europe and also recombinant factor IX for the treatment of hemophilia B has been licensed in the United States and Europe.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP283433.RAx-wIbS7SBTto0kKIdQRCmUOiq6EuMgtr2w1QhdxgLtQ130_provenance.